June 2018 Johns Hopkins Bloomberg School of Public Health International Vaccine Access Center IVAC Developed from information in the VIEWhub databaseplatform For other VIEWhubrelated inquiries please contact Kirthini Muralidharan at ID: 1028758
Download Presentation The PPT/PDF document "IVAC VIEW-hub Global Vaccine Introductio..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. IVAC VIEW-hub Global Vaccine Introduction and Implementation ReportJune 2018Johns Hopkins Bloomberg School of Public HealthInternational Vaccine Access Center (IVAC)Developed from information in the VIEW-hub database/platformFor other VIEW-hub-related inquiries, please contact Kirthini Muralidharan at kmurali2@jhu.eduVIEW-hub Report: Global Vaccine Introduction and Implementation
2. Historical PCV vs. Rotavirus Vaccine Introduction, by Income GroupNote: Limited projections are available for high income countries.Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.
3. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Historical PCV Introduction by Income GroupNote: Limited projections are available for high, upper-middle, and lower-middle income countries
4. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Historical Rotavirus Vaccine Introduction by Income GroupNote: Limited projections are available for high, upper-middle, and lower-middle income countries
5. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Historical IPV Introduction by Income GroupNote: Limited projections are available for high, upper-middle, and lower-middle income countries
6. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Global Introduction Status of Hib VaccineIntroduced – National (190)Introduced – Subnational (1)Introduced – Risk Program (1)
7. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Global PCV Introduction Status by YearTarget: 194 countries
8. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Global PCV Introduction Status
9. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Global Introduction Status of PCVIntroduced – National (134)Introduced – Subnational (5)Introduced – Risk Program (3)
10. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.PCV – Current ProductPCV10 (31)PCV13 (103)PCV10 and PCV13 (8)Gavi countries
11. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.PCV – Current Dosing Schedule2+1 (57)3+0 (59)3+1 (23)2+1 and 3+1 (1)Gavi countries
12. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Global Coverage and Access to PCV
13. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Gavi PCV Introduction Status by YearTarget: 73 countries
14. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Gavi PCV Introduction Status
15. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Gavi Countries’ Introduction Status of PCVIntroduced – National (56)Introduced – Subnational (3)Not Introduced (14)
16. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Coverage and Access to PCV in Gavi Countries
17. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Global Rotavirus Vaccine Introduction Status by Year Target: 194 countries
18. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Global Rotavirus Vaccine Introduction Status
19. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018. Global Introduction Status of Rotavirus VaccineIntroduced – National (90)Introduced – Subnational (6)
20. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Rotavirus Vaccine – Current ProductRV1 (74)RV1 - Rotavac (1)RV5 (14)RV1 and RV5 (7)Gavi countries
21. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Rotavirus Vaccine – Current Dosing Schedule2+0 (73)3+0 (15)2+0 and 3+0 (7)Gavi countries
22. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Global Coverage and Access to Rotavirus Vaccine
23. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Gavi Rotavirus Vaccine Introduction Status by Year Target: 73 countries
24. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Gavi Rotavirus Vaccine Introduction Status
25. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018. Gavi Countries’ Introduction Status of Rotavirus Vaccine Introduced – National (45)Introduced – Subnational (1)Not Introduced (27)
26. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Coverage and Access to Rotavirus Vaccine in Gavi Countries
27. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Global IPV Introduction Status by Year Target: 194 countries
28. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Global IPV Introduction Status
29. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018. Global Introduction Status of IPVIntroduced – National (182)Introduced – Subnational (5)Countries using IPV without OPV (49)Note: All other IPV-using countries are also using OPV in their national schedule.
30. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.IPV – Current ProductIPV (Stand alone) (115)Combination vaccine (56)Multiple formulations (14)Product unknown (2)Gavi countries
31. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.IPV– Current Dosing Schedule1+0 (102)2+0 (14)2+1 (11)3+0 and/or 3+1 (60)
32. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Global Coverage and Access to IPV
33. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Gavi IPV Introduction Status by Year Target: 73 countries
34. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Gavi IPV Introduction Status
35. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018. Gavi Countries’ Introduction Status of IPVIntroduced – National (64)Introduced – Subnational (3)Not Introduced (6)
36. Source: International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2018.Coverage and Access to IPV in Gavi Countries
37. Acknowledgements and NotesThis report is developed by the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health, with support from Gavi, the Bill & Melinda Gates Foundation, The Task Force for Global Health and ROTA Council.Please note that all forecasted introductions in this report rest on assumptions and may vary. Planned vaccine introduction dates do not imply an obligation by Gavi to support coverage.Definitions and sources are available in VIEW-hub at www.VIEW-hub.org. The most current VIEW-hub Report and matching slides can be found at: http://ivac.jhu.edu/resources/view-hub-reports/. For any VIEW-hub-related inquiries, please email Kirthini Muralidharan at kmurali2@jhu.edu.